Apixaban vs Rivaroxaban: Scoping Review with ☸️SAIMSARA
SAIMSARA Journal · 05.05.2026 · 1 (1)
DOI: 10.62487/saimsarae6ee9492 ↗Kurz gefasst
Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 05.05.2026. Die Arbeit nennt 177 Literaturangaben.
Abstract (Originalsprache)
This review aims to synthesize current evidence comparing apixaban and rivaroxaban regarding clinical effectiveness, safety outcomes (specifically bleeding risks), and pharmacological performance across diverse patient populations and clinical scenarios. The review utilises 995 original studies with 26655215 total participants (topic deduplicated ΣN). Across the mapped evidence, apixaban emerged as the agent with a more favorable bleeding profile compared with rivaroxaban, with hazard ratios for major bleeding ranging from 0.50 to 0.86 and for gastrointestinal bleeding from 0.33 to 0.72, while effectiveness for stroke and recurrent VTE prevention was largely comparable. This signal was consistent across diverse clinical contexts including advanced CKD, cirrhosis, diabetes, valvular heart disease, HIV, peripheral artery disease, and the very elderly, and was reinforced by pharmacokinetic observations of more stable apixaban exposure (peak-to-trough ratio 4.7 vs 16.9) and by pharmacovigilance signals favoring apixaban for hematuria, uterine bleeding, and hepatic injury. Notable countervailing signals included occasional VTE readmission and mortality findings favoring rivaroxaban, mixed endoscopic and orthopedic results, and adherence data sometimes favoring once-daily rivaroxaban, indicating that the choice between agents is not uniformly directional. The clinical implication supported by this evidence map is that apixaban may be preferentially considered in patients with elevated bleeding risk, renal or hepatic impairment, or concomitant antiplatelet therapy, while recognizing that channeling bias and the predominance of observational data temper certainty. Future research should prioritize randomized head-to-head comparisons in cirrhosis, advanced CKD, cancer-associated VTE, and women with heavy menstrual bleeding, alongside refined dosing and monitoring protocols for patients with bariatric surgery, antiseizure medication co-therapy, or extreme body weight.
Zitieren
APA
(2026). Apixaban vs Rivaroxaban: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsarae6ee9492
Vancouver
Apixaban vs Rivaroxaban: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsarae6ee9492
BibTeX
@article{euvimed2026,
title = {Apixaban vs Rivaroxaban: Scoping Review with ☸️SAIMSARA},
journal = {SAIMSARA Journal},
year = {2026},
volume = {1},
number = {1},
doi = {10.62487/saimsarae6ee9492}
}
EUVIMED